目的 探討蒲地藍消炎口服液聯(lián)合重組人干擾素α1b注射液治療普通型手足口病的臨床療效。方法 選取2013年10月-2015年10月在蘇州市立醫(yī)院進行治療的普通型手足口病患兒97例，按照治療方式的不同分為對照組（42例）和治療組（55例）。對照組肌肉注射重組人干擾素α1b注射液，10 μg/次，1次/d。治療組在對照組基礎(chǔ)上口服蒲地藍消炎口服液，5～10 mL/次，3次/d。兩組患兒均治療7 d。觀察兩組的臨床療效，比較兩組的癥狀消失時間和進食情況。結(jié)果 治療后，對照組和治療組的總有效率分別為80.95%、94.55%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，治療組退熱時間、皮疹消退時間、口腔黏膜充血和潰瘍恢復(fù)時間、總病程均明顯短于對照組，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療3、5 d后，對照組進食為“好”的占比分別為42.86%、69.05%；治療組進食為“好”的占比分別為56.36%、81.82%，兩組比較差異有統(tǒng)計學意義（P<0.05）。結(jié)論 蒲地藍消炎口服液聯(lián)合重組人干擾素α1b注射液治療普通型手足口病具有較好的臨床療效，可改善臨床癥狀，縮短病程，改善患兒進食情況，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Pudilan Xiaoyan Oral Liquid combined with Recombinant Human Interferon α1b Injection in treatment of children with common hand-foot-and-mouth disease. Methods Children (97 cases) with common hand-foot-and-mouth disease in Suzhou Municipal Hospital from October 2013 to October 2015 were enrolled in this study. According to the difference treatment plan, children were divided into control group (42 cases) and treatment group (55 cases). Children in the control group were im administered with Recombinant Human Interferon α1b Injection, 10 μg/time, once daily. Children in the treatment group were po administered with Pudilan Xiaoyan Oral Liquid on the basis of the control group, 5-10 mL/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacies were evaluated, and symptom disappearance time and eating condition in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.95% and 94.55%, respectively, and there was difference between two groups (P<0.05). After treatment, pyretolysis time, skin rash subsided time, oral mucosal congestion and ulcer recovery time, and disease duration in the treatment group were significantly shorter than those in the control group, and there was difference between two groups (P<0.05). After treatment for 3 d and 5 d, the percentage of eating condition as "good" in the control group were 42.86% and 69.05%, respectively, but the percentage of eating condition as "good" in the treatment group were 56.36% and 81.82%, respectively, and there was difference between two groups (P<0.05). Conclusion Pudilan Xiaoyan Oral Liquid combined with Recombinant Human Interferon α1b Injection has clinical curative effect in treatment of children with common hand-foot-and-mouth disease, can improve clinical symptom, shorten disease duration, and improve eating condition, which has a certain clinical application value.